Sai Life Sciences Ltd

The Board of Sai Life Sciences at its meeting held on 09 June 2025 has approved and allotted 19,000 equity shares under ESOP. Powered by Capital Market - Live

EBITDA jumped 42% year-on-year (YoY) to Rs 425 crore in Q4FY25. EBITDA margin improved to 25% in Q4 FY25, compared to 20% in Q4 FY24. Profit before tax rose 108% YoY to Rs 228 crore in Q4FY25. For the full year, net profit rose 57% to Rs 88 crore on 32% increase in revenue from operations to Rs 580 crore in the year ended March 2025 over the year ended March 2024. EBITDA rose 30% YoY to Rs 161 crore in FY25. EBITDA margin was unchaged at 28% in FY25. PBT climbed 56% YoY to Rs 119 crore in FY25. Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said, We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.' Siva Chittor, director and chief financial officer, Sai Life Sciences added, We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at Rs 408 Cr, focused on enhancing our manufacturing footprint and expanding discovery capabilities. We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders. Hyderabad-based Sai Life Sciences is a leading global contract research, development, and manufacturing organization (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. The company offers integrated solutions spanning medicinal chemistry, process development, clinical and commercial manufacturing, and advanced technology platforms. Powered by Capital Market - Live

Sai Life Sciences has allotted 25,000 equity shares under ESOPs on 13 May 2025. Powered by Capital Market - Live

Net profit of Sai Life Sciences rose 57.26% to Rs 88.27 crore in the quarter ended March 2025 as against Rs 56.13 crore during the previous quarter ended March 2024. Sales rose 31.94% to Rs 579.51 crore in the quarter ended March 2025 as against Rs 439.21 crore during the previous quarter ended March 2024. For the full year,net profit rose 105.45% to Rs 170.13 crore in the year ended March 2025 as against Rs 82.81 crore during the previous year ended March 2024. Sales rose 15.66% to Rs 1694.57 crore in the year ended March 2025 as against Rs 1465.18 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales579.51439.21 32 1694.571465.18 16 OPM %27.1928.38 -23.9419.48 - PBDT156.29107.11 46 366.28228.67 60 PBT118.8076.05 56 227.70109.23 108 NP88.2756.13 57 170.1382.81 105 Powered by Capital Market - Live

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live

Data Patterns (India) Ltd, K E C International Ltd, Elgi Equipments Ltd, Doms Industries Ltd are among the other stocks to see a surge in volumes on NSE today, 15 April 2025.Sai Life Sciences Ltd recorded volume of 48.83 lakh shares by 14:14 IST on NSE, a 12.31 times surge over two-week average daily volume of 3.97 lakh shares. The stock gained 13.38% to Rs.759.05. Volumes stood at 1.87 lakh shares in the last session.Data Patterns (India) Ltd notched up volume of 48 lakh shares by 14:14 IST on NSE, a 10.71 fold spurt over two-week average daily volume of 4.48 lakh shares. The stock rose 12.36% to Rs.1,889.80. Volumes stood at 2.66 lakh shares in the last session.K E C International Ltd registered volume of 56.9 lakh shares by 14:14 IST on NSE, a 4.47 fold spurt over two-week average daily volume of 12.72 lakh shares. The stock rose 8.39% to Rs.715.45. Volumes stood at 10.04 lakh shares in the last session.Elgi Equipments Ltd saw volume of 29.6 lakh shares by 14:14 IST on NSE, a 4.43 fold spurt over two-week average daily volume of 6.68 lakh shares. The stock increased 5.55% to Rs.445.60. Volumes stood at 21.07 lakh shares in the last session.Doms Industries Ltd clocked volume of 4.43 lakh shares by 14:14 IST on NSE, a 4.38 times surge over two-week average daily volume of 1.01 lakh shares. The stock gained 1.61% to Rs.2,641.30. Volumes stood at 97276 shares in the last session.Powered by Capital Market - Live

 Sai Life Sciences has inaugurated a dedicated Peptide Research Center at its integrated R&D Campus in Hyderabad, India. The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates. The facility integrates automation, advanced liquid handling, robotics, and high-throughput systems, enhancing precision, scalability, and efficiency in the development of novel peptide-based therapeutics. Maneesh Pingle, Head of Discovery Services, said: 'The demand for peptide-based therapeutics is rising rapidly, driven by their high specificity, biocompatibility, and lower risk of off-target effects. At Sai Life Sciences, we have a seasoned team of scientists with years of experience successfully delivering peptide discovery and development projects. Combined with our expanding capabilities, this expertise positions us strongly to support our clients' evolving needs as they advance peptide therapies across diverse therapeutic areas.Powered by Capital Market - Live

Net profit of Sai Life Sciences rose 35.95% to Rs 53.85 crore in the quarter ended December 2024 as against Rs 39.61 crore during the previous quarter ended December 2023. Sales rose 14.64% to Rs 439.78 crore in the quarter ended December 2024 as against Rs 383.63 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales439.78383.63 15 OPM %27.2325.11 - PBDT105.7484.35 25 PBT71.6552.94 35 NP53.8539.61 36 Powered by Capital Market - Live